TickerFacts.

Company research / INSM

Insmed Inc (INSM)

Build a valuation ↗↓ Download CSV

SEC name INSMED Inc · CIK 0001104506 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated VA
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Insmed Inc reported revenue of $606.42M. Revenue grew 66.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $1.14B.

Key ratios (year ended 2025-12-31)

79.7%
Gross margin (computed)
-205.6%
Operating margin
-210.5%
Net margin
-172.8%
Return on year-end equity
66.7%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-20

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$1.14B$606.42M$363.71M$305.21M$245.36M$188.46M$164.41M$136.47M$9.84M$0$0
Cost of Revenue$188.22M$122.94M$85.74M$65.57M$55.13M$44.15M$39.87M$24.21M$2.42M$0$0
Gross Profit$949.42M$483.49M$277.96M$239.63M$190.23M$144.31M$124.54M$112.25M$7.41M$0n/a
R&D Expense$860.85M$771.09M$598.37M$571.01M$397.52M$272.74M$181.16M$131.71M$145.28M$109.75M$122.72M
Operating Income-$840.62M-$1.25B-$878.25M-$709.63M-$457.32M-$375.09M-$265.23M-$235.25M-$307.34M-$188.92M-$173.40M
Depreciation & Amortizationn/an/an/a$5.50M$5.30M$9.10M$9.10M$5.20M$3.60M$2.90M$2.40M
EBITDAn/an/an/a-$704.13M-$452.02M-$365.99M-$256.13M-$230.04M-$303.74M-$186.02M-$171.00M
Net Income-$875.31M-$1.28B-$913.77M-$749.57M-$481.53M-$434.65M-$294.09M-$254.34M-$324.28M-$192.65M-$176.27M
EPS (Diluted)n/a-$6.42-$5.57-$5.34-$3.91-$3.88-$3.01-$3.01n/an/an/a
Total Assets$2.10B$2.26B$2.03B$1.33B$1.66B$1.24B$796.15M$742.30M$604.56M$462.05M$237.96M
Total Liabilities$1.35B$1.53B$1.74B$1.66B$1.57B$833.04M$520.27M$480.62M$396.29M$100.99M$83.47M
Long-Term Debt$546.77M$546.77M$1.12B$1.18B$1.15B$800.00M$450.00M$450.00M$450.00M$55.00M$55.00M
Shareholders' Equity$757.49M$738.98M$285.38M-$331.92M$87.95M$410.47M$275.88M$261.67M$208.27M$361.06M$154.48M
Cash & Equivalents$544.76M$510.44M$555.03M$482.37M$1.07B$716.78M$532.76M$487.43M$495.07M$381.17M$162.59M
Operating Cash Flow-$778.92M-$935.01M-$683.88M-$536.25M-$400.44M-$363.30M-$219.35M-$250.65M-$257.98M-$159.62M-$146.71M
Capital Expenditures$28.75M$32.56M$21.92M$13.29M$9.88M$7.29M$6.24M$42.27M$13.09M$3.00M$4.20M
Free Cash Flow-$807.67M-$967.58M-$705.80M-$549.53M-$410.32M-$370.59M-$225.59M-$292.92M-$271.07M-$162.62M-$150.91M
Shares Outstanding218.28M214.26M179.38M147.98M135.65M118.74M102.76M89.68M77.31M76.61M62.02M
Weighted Average Diluted Sharesn/a199.01M164.04M140.43M123.03M112.11M97.61M84.56M76.89M66.58M61.89M
EPS (Basic)n/a-$6.42-$5.57-$5.34-$3.91-$3.88-$3.01-$3.01n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView